LGND Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
78.7M
+23.6%
63.7M
+23.1%
51.7M
-13.3%
59.7M
-48.3%
115.5M
Cost of Revenue
12.9M
+13.7%
11.3M
-0.5%
11.4M
+280.0%
3.0M
-74.9%
11.9M
Gross Profit
65.9M
+25.8%
52.4M
+29.8%
40.4M
-28.8%
56.7M
-45.3%
103.6M
Operating Expenses
81.6M
+86.5%
43.8M
+90.5%
23.0M
-46.3%
42.8M
-12.6%
49.0M
R&D
2.8M
-81.1%
14.7M
+582.9%
2.1M
-38.8%
3.5M
-83.3%
21.0M
SG&A
72.6M
+149.3%
29.1M
+39.8%
20.8M
-16.7%
25.0M
-12.0%
28.4M
Operating Income
-15758000
-283.4%
8.6M
-50.5%
17.4M
+25.5%
13.8M
-74.6%
54.6M
EBITDA
-5435000
-132.3%
16.8M
-34.3%
25.6M
-9.4%
28.3M
-55.0%
62.8M
Net Income
-28485000
-158.7%
48.5M
+463.5%
-13345000
-129.8%
44.8M
-61.8%
117.3M
EPS (Basic)
$-1.43
-159.1%
$2.42
+461.2%
$-0.67
-128.8%
$2.33
-61.1%
$5.99
EPS (Diluted)
$-1.43
-164.4%
$2.22
+431.3%
$-0.67
-132.1%
$2.09
-63.2%
$5.68
Shares (Diluted)
20.0M
-8.6%
21.8M
+9.8%
19.9M
-7.2%
21.4M
+3.9%
20.6M
Ligand Pharmaceuticals (LGND) — Financials